Kuo YJ, et al. – Aim was to explore the correlation between αIIbβ3 binding epitopes and induction of drug-dependent antibody (DDAb) binding to conformation–altered αIIbβ3. To accomplish that, this study tried to investigate whether two purified disintegrins TMV–2 and TMV–7 with distinct binding motifs that had different effects on induction of αIIbβ3 conformational change and platelet aggregation in the presence of AP2, an IgG1 inhibitory monoclonal antibody (mAb) raised against αIIbβ3. Via a mechanism different from all other tested αIIbβ3 antagonists, TMV–7 displayed antiplatelet and antithrombotic activities. In addition, it appeared to offer advantages as a therapeutic agent with a better safety profile.